<DOC>
	<DOCNO>NCT02690038</DOCNO>
	<brief_summary>This study look immunoglobulin ( Ig ) treatment hospitalize chronic obstructive lung disease ( COPD ) patient frequent exacerbation . This Phase II , pilot randomize double blind control study , mean study help assess research expand evaluate Ig treatment patient COPD . Ig treatment sterile solution human immunoglobulin protein give intravenously ( vein ) . Immunoglobulins part immune system help body fight infection . Participants assign either receive Ig treatment normal saline control product every 4 week 12 month . Participants continue current standard therapy determine treat physician .</brief_summary>
	<brief_title>Ig PRx AECOPD : Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Hospitalized adult patient AECOPD ( clinically dominant AECOPD case multiple comorbidities eg . absence overt lobar pneumonia acute congestive heart failure alternate diagnosis acute coronary syndrome pulmonary embolism ) Diagnosis severe COPD ( post bronchodilator FEV1 &lt; 50 % , FEV1/FVC ratio &lt; 0.7 ) make standard spirometry within previous 12 month within three day admission previous PFT data available Age &gt; 40 year &gt; 10 pack year smoke history At least one COPD exacerbation previous 12 month enrollment , define document inpatient outpatient treatment physician antibiotic and/or prednisone physician diagnose COPD exacerbation Expected live &gt; 12 month Known severe hypersensitivity immunoglobulin component ( anaphylaxis ) Underlying malignancy ( include chronic lymphocytic leukemia ) History hematopoietic stem cell transplant solid organ transplant Current treatment biological therapy condition Concomitant significant immunodeficiency immunosuppressive treatment COPD Alpha1 antitrypsin deficiency Significant proteinuria ( dipstick proteinuria ≥ 3+ know urinary protein loss ≥ 2 g/day nephrotic syndrome ) and/or acute renal failure and/or severe renal impairment ( creatinine 2.5 time upper limit normal and/or dialysis ) IgA deficiency ( IgA &lt; 0.1 g/L ) Immunoglobulin therapy last 12 month current Ig therapy clinical indication Ig replacement therapy ( www.nacblood.ca/resources/guidelines/IVIG.html ) Obesity ( BMI ≥35 kg/m² ) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>AECOPD</keyword>
	<keyword>COPD</keyword>
</DOC>